Immutep's Eftilagimod Alfa Combination Shows Positive Phase IIb Results In Head & Neck Cancer Trial
12/7 04:44
(RTTNews) - Immutep Limited (IMMP, IMM.AX) announced positive results from Cohort B of the TACTI-003 (KEYNOTE-PNC-34) Phase IIb trial evaluating eftilagimod alfa (efti) in combination with Merck & Co., Inc.'s (MRK) anti-PD-1 therapy KEYTRUDA (pembrolizumab) as first-line treatmen...